Skip to main content
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1984 Dec;18(3):164–168. doi: 10.1007/BF00205506

Effects of cefotaxime, clindamycin, mezlocillin, and piperacillin on mouse sarcoma L-1 tumor

K Roszkowski 1, H L Ko 2, W Roszkowski 1, J Jeljaszewicz 3, G Pulverer 2,
PMCID: PMC11039224  PMID: 6095992

Abstract

For the study described in the paper, the effects of 10 days' chemotherapy with cefotaxime, clindamycin, mezlocillin, and piperacillin on local tumor growth and on spontaneous or artificial metastatic spread into the lungs were studied. For the animal tumor model Balb/c mice and the mouse sarcoma L-1 tumor were used. Chemotherapy was administered before, immediately after, or some time after the injection of tumor cells. The antibiotic dosage given to mice was calculated on a body weight basis from the doses recommended for humans. Cefotaxime and clindamycin did not influence the animal tumor model, whereas mezlocillin and piperacillin showed positive or negative effects depending on the chemotherapy schedule. In vitro none of the four antibiotics caused cytotoxic activity in cell cultures of mouse sarcoma L-1, human lung cancer E-14, or human malignant melanoma MEW.

Keywords: Lung Cancer, Malignant Melanoma, Sarcoma, Local Tumor, Cytotoxic Activity

Footnotes

Fellows of the Alexander von Humboldt Foundation

References

  • 1.Becker S, Kiessling R, Lee N, Klein G. Modulation of sensitivity of natural killer cell lysis after in vitro explantation of mouse lymphoma. J Natl Cancer Inst. 1978;61:1495–1498. [PubMed] [Google Scholar]
  • 2.Bodey GP, Bockley M, Sathe YS, Freireich EJ. Quantitative relationship between circulating leukocytes and infection in patients with acute leukaemia. Ann Intern Med. 1966;64:328–340. doi: 10.7326/0003-4819-64-2-328. [DOI] [PubMed] [Google Scholar]
  • 3.Bodey GP, Hersh EM, Validiviese M. Effects of cytotoxic drugs and immunosuppressive agents on the immune system. Postgrad Med J. 1975;58:67–74. doi: 10.1080/00325481.1975.11714222. [DOI] [PubMed] [Google Scholar]
  • 4.Fainstein V, Bodey GP. Bacterial infections in cancer patients. An overview. In: Jeljaszewicz J, Pulverer G, Roszkowski W, editors. Bacteria and cancer. London New York: Academic Press; 1982. pp. 435–451. [Google Scholar]
  • 5.Finch R. Immunomodulating effects of antimicrobial agents. J Antimicrob Chemother. 1980;6:691–693. doi: 10.1093/jac/6.6.691. [DOI] [PubMed] [Google Scholar]
  • 6.Hanna N, Burton RC. Definite evidence that natural killer cells inhibit experimental tumor metastasis in vivo. J Immunol. 1981;127:1754–1758. [PubMed] [Google Scholar]
  • 7.Hill RP, Bush RS. A lung colony assay to determine radiosensitivity of the cells of a solid tumor. Int J Radiat Biol. 1969;15:435–444. doi: 10.1080/09553006914550721. [DOI] [PubMed] [Google Scholar]
  • 8.Roszkowski W, Lipinska R, Roszkowski K, Jeljaszewicz J, Pulverer G. Rifampicin-induced suppression of antitumor immunity. Med Microbiol Immunol. 1984;172:197–205. doi: 10.1007/BF02123714. [DOI] [PubMed] [Google Scholar]
  • 9.Roszkowski W, Ko HL, Jeljaszewicz J, Pulverer G (1984) Antibiotics and host immunity: Effects of cefotaxime, amikacin and mezlocillin. Zentralbl Bakteriol [Orig A] Suppl. 13 (in press)
  • 10.Ruben FL, Winkelstein A, Fotadis IG, Dessauer P. Rifampicin and immunosuppression. Lancet. 1973;2:978. doi: 10.1016/s0140-6736(73)92651-2. [DOI] [PubMed] [Google Scholar]
  • 11.Weissman IL. Tumor immunology, T cell maturation and T cell neoplasia. Prog Exp Tumor Res. 1980;25:193–218. doi: 10.1159/000403182. [DOI] [PubMed] [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES